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INTRODUCTION
Need
Colorectal cancer (CRC) is the third most common cancer 
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worldwide. According to the data
1 reported in 2008 by the 
Korean Collaborating Center for Cancer Registration, there 
were 22,623 cases of domestic CRC for men and women 
combined. Moreover, CRC represented 12.7% of all cancers 
and was the third most common type of newly diagnosed can-
cer. Among men, there were 13,536 cases of CRC, which made 
this the second most common cancer in men. In women, 
there were 9,087 cases of CRC, which made this the fourth 
most common cancer among women.
Furthermore, the crude incidence rate of CRC is 45.8 cases 
per 100,000 individuals, and this incidence has been increas-
ing steadily since the data analysis began in 1999. Eighty per-
cent of CRCs originate as adenomatous polyps. Polyps are 
precancerous lesions and can develop into carcinomas over a 
period of 5 to 10 years through a process known as the “ade-
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There is indirect evidence to suggest that 80% of colorectal cancers (CRC) develop from adenomatous polyps and that, on average, it 
takes 10 years for a small polyp to transform into invasive CRC. In multiple cohort studies, colonoscopic polypectomy has been shown 
to significantly reduce the expected incidence of CRC by 76% to 90%. Colonoscopic polypectomy is performed frequently in primary 
outpatient clinics and secondary and tertiary medical centers in Korea. However, there are no evidence-based, procedural guidelines for 
the appropriate performance of this procedure, including the technical aspects. For the guideline presented here, PubMed, Medline, and 
Cochrane Library literature searches were performed. When little or no data from well-designed prospective trials were available, an 
emphasis was placed on the results from large series and reports from recognized experts. Thus, these guidelines for colonoscopic pol-
ypectomy are based on a critical review of the available data as well as expert consensus. Further controlled clinical studies are needed to 
clarify aspects of this statement, and revision may be necessary as new data become available. This guideline is intended to be an educa-
tional device to provide information that may assist endoscopists in providing care to patients. This guideline is not a rule and should 
not be construed as a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment. Clinical 
decisions for any particular case involve a complex analysis of the patient’s condition and the available courses of action. 
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noma-carcinoma sequence.” Therefore, if adenomatous pol-
yps are detected and removed through aggressive screening, 
the mortality rate of CRC can be significantly reduced. Re-
cently, as domestic awareness of CRC has increased, the num-
ber of colonoscopies performed has also increased rapidly. 
Polypectomy is commonly performed for polyps that are de-
tected during colonoscopic examinations not only in second-
ary or tertiary medical centers but also in primary outpatient 
clinics. However, it is difficult to find domestic or interna-
tional evidence-based guidelines regarding colonoscopic poly-
pectomy procedures. Moreover, education and training for 
providers who perform colonoscopic polypectomy are avail-
able only at tertiary medical centers. Therefore, the develop-
ment of an appropriate colonoscopic polypectomy guideline 
will assist numerous physicians who perform colonoscopic 
polypectomies within the Korean health care system. We hope 
that implementation of these guidelines will improve the uti-
lization of limited medical resources and result in socioeco-
nomic gain from the secondary prevention of CRC.
Purpose
This guideline has systematically incorporated the current 
domestic and foreign literature regarding 6 key questions re-
lated to colonoscopic polypectomy to establish an appropri-
ate guideline to fit our country’s current medical circum-
stances. Our objectives were to assist medical providers who 
perform colonoscopic polypectomy, to improve the quality 
of care, and to provide patients with appropriate and balan-
ced information.
Limitations
The limited data on this subject presented an obstacle for 
compiling this domestic guideline for colonoscopic polypec-
tomy. Most of the available data are from a limited number 
of North American and European studies, which evaluated 
epidemiologic characteristics that are not applicable to Kore-
an patients. To overcome these limitations, we first created a 
draft treatment guideline based on the domestic and foreign 
research literature and then utilized a web-based survey to 
better understand the clinical practices of Korean endosco-
pists performing colonoscopic polypectomies. Based on this 
information, we summarized the opinions of domestic ex-
perts using the Delphi method. 
However, because the Western researches that were used 
as the basis for half of the key questions were mostly com-
prised of observational studies rather than randomized con-
trolled trials, the quality of the evidence for the recommen-
dations was low. Therefore, the strength of the recommen-
dations was evaluated mainly by collecting the opinions of 
domestic experts. Furthermore, even for those key questions 
where a meta-analysis of randomized controlled trials was 
available, the characteristics of the polyps were different, the 
number of patients included was relatively small considering 
the complication rates, and there were limitations due to dif-
ferences in the statistical methods applied. Also, because this 
guideline cannot deal with every aspect of endoscopic treat-
ment methods, a guideline with more diverse key questions 
should also be created. The 6 most relevant key questions for 
endoscopists regarding polypectomy are included in this 
guideline.
The participants and the process 
The creation of the guideline began in June 2010 by form-
ing the practice committee for the Colorectal Polyp Treat-
ment Guidelines. This committee included academic experts 
from multiple societies: experts were recommended by the 
Korean Society of Gastroenterology, the Korean Society of 
Gastrointestinal Endoscopy, the Korean Association for the 
Study of Intestinal Diseases, and the Korean Society of Ab-
dominal Radiology. The guidelines were divided into three 
topics: screening, surveillance, and treatment. Subsequently, 
a task force was assigned to each topic. No participant de-
clared a conflict of interest. 
Supply and practice 
These guidelines will be published on the websites of the 
Korean Journal of Gastroenterology, the Korean Society of 
Gastrointestinal Endoscopy, the Korean Association for the 
Study of Intestinal Diseases, and the Korean Society of Ab-
dominal Radiology. We also plan to prepare a summary con-
sisting of important recommendations that would be sup-
plied free of charge to front-line medical professionals. 
METHODS
Selecting key questions
Because this guideline could not incorporate all issues rel-
evant to colonoscopic polypectomy, the practice committee 
of the treatment task force selected 6 key questions. 
Literature search
For the literature search, clinical trials, comparison studies, 
randomized controlled trials, meta-analyses, and treatment 
guidelines for colonoscopic polypectomy released in English 
between January 1, 2000 and September 2010, were searched 
using PubMed, Medline, and the Cochrane Library search 
engine. The key words that were used for the English search 
included the MeSH terminologies of hemorrhage, blood, en-
doscopy, mucous membrane, salicylic acid, aspirin, sodium 
chloride, epinephrine, vasoconstrictor agents, surgical in-SH Lee et al. 
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struments, and argon plasma. The general text words that 
were included in the search were acetylsalicylic acid, ASA, 
acetyl-salicylic acid, Migramax, Migpriv, Migrafin, Migra-
vess, saline injections, epinephrine injections, adrenaline in-
jections, post-polypectomy, endoscopic resection, endoscop-
ic mucosal resection, diminutive polyp, small polyp, detach-
able snare, endoloop, endoclip, hemoclip, clip, and argon pla-
sma. These additional terms were used because many rele-
vant key words are not defined in the MeSH terminologies. 
The literature search results for each key question are includ-
ed in the appendix. We excluded irrelevant pieces of litera-
ture by screening the titles and abstracts of the paper as well 
as the full text when necessary. We excluded 833 foreign pa-
pers and selected 52 papers for further analysis. Then, after a 
thorough examination of the full text of each paper, a stan-
dardized evidence table was created for the extraction of data 
relevant to the key questions.
Meta-analysis
A meta-analysis was performed only for key questions that 
could be informed by relevant randomized controlled trials. 
The odds ratios (OR) or the relative risk (RR) related to dif-
ferences in treatment effects as well as the standard error and 
the 95% confidence interval (CI) were calculated. If the dif-
ference in the treatment effect was presented as a hazard ra-
tio, it was included in the evidence table but excluded from 
the meta-analysis. Because the combined analysis included 
independent effects of individual risk factors from the un-
processed data of the included individual trials, the data were 
extracted with priority given to the individual trials. There-
fore, the data extracted from individual trials that were in-
cluded in the combined analysis were excluded from the me-
ta-analysis. Studies were treated as observational studies, 
even when structured as randomized controlled trials, if the 
data were extracted from all cohorts participating in the re-
search. Because of the heterogeneity in patient characteris-
tics, research plans, follow-up periods, and purpose points 
among the trials selected for the meta-analysis, the random-
effect model was used as the statistical model, and the inverse 
variance weighted estimation method was used for the effec-
tiveness measurement to calculate pooled estimates. If the 
Cochrane Q-black test showed p-values of <0.1, statistical 
heterogeneity was considered to exist. The meta-analysis was 
performed using RevMan version 5.1 software (The Co-
chrane Collaboration, Oxford, UK).
Quality of evidence and strength  
of recommendations 
Recommendations are presented based on a systematic re-
view of the selected literature and meta-analyses. The quality 
of evidence, indicating the degree to which each recommen-
dation has scientific evidence, and the strength of the recom-
mendations were determined following the methodology 
proposed by the Grading of Recommendations Assessment, 
Development and Evaluation Working Group (Table 1).2,3
The quality of evidence was assessed to be “high” when 
evidence consisted of randomized controlled trials and “low” 
in cases where evidence included observational studies. 
However, in cases where studies used as evidence had limita-
tions in the study design or execution, inconsistent results, 
indirect evidence, imprecise results or publication bias, the 
quality of evidence was adjusted downward. In cases of ob-
servational studies where large effects were observed, where 
reported effects might have been reduced due to confound-
ing variables or where dose-response gradients existed, the 
quality of evidence was adjusted upward. The strength of 
each recommendation was assessed as “strong” or “weak” by 
considering the balance of desirable and undesirable conse-
quences, the quality of the evidence, the confidence in the 
values and the references and the effective allocation of med-
ical expenses and resources. That is, in cases where it was 
judged that following a specific recommendation would lead 
to significant health benefits or losses for most patients, the 
strength of the recommendation was classified as “strong”. 
Table 1. Quality of Evidence and the Strength of the Recommendation
Quality of evidence
High quality  Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality   Further research is likely to have an important impact on our confidence in the estimate of effect and may 
   change the estimate
Low quality   Further research is very likely to have an important impact on our confidence in the estimate of effect and 
   is likely to change the estimate
Very low quality  Any estimate of effect is very uncertain
Strength of a recommendation 
Strong recommendation Most or all individuals will be best served by the recommended course of action
Weak recommendation  Not all individuals will be best served by the recommended course of action. There is a need to consider  
   more carefully than usual individual patient’s circumstances, preferences, and values14  Clin Endosc 2012;45:11-24
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The strength of the recommendation was classified as “weak” 
in cases where it was judged that following the recommenda-
tion would lead to important benefits or loss in terms of the 
quality of the health of patients but where differences existed 
among patients, thus leading to the need to consider individ-
ual environments, preferences and values.2,3
GUIDELINES FOR COLONOSCOPIC  
POLYPECTOMY
Should aspirin be discontinued prior to the polypectomy 
due to the danger of post-polypectomy bleeding?
The use of aspirin should continue prior to the polypecto-
my for individuals with a high risk of developing thrombo-
embolism. For those with a lower risk of developing throm-
boembolism, the aspririn treatment regimen should be 
determined according to the characteristics of the patients 
and their polyps. For those with no risk of developing throm-
boembolism, it is recommended that aspirin treatment be 
discontinued prior to polypectomy.
· Quality of evidence: very low quality
· Strength of recommendation: weak recommendation
· Level of agreement: completely agree (7%), generally 
agree (75%), partially agree (18%), generally disagree 
(0%), completely disagree (0%) 
When performing endoscopic procedures on patients tak-
ing anti-platelet agents, such as aspirin, the risk of bleeding 
due to the drug or the endoscopic procedure itself must be 
considered, and this risk should be compared to that of the 
development of thromboembolism following anti-platelet 
treatment discontinuation. 
Aspirin causes the irreversible inactivation of cyclooxygen-
ase (COX) in platelets and blocks the production of throm-
boxane, which is necessary for the agglutination reaction of 
platelets. The half-life of aspirin in the blood can be as short 
as 20 minutes, but its inhibition of COX is maintained for the 
lifespan of the platelet. Even after a single administration of 
low-dose aspirin, the inhibition of platelet agglutination is 
maintained for 7 to 10 days. A study that measured the bleed-
ing times of 11 healthy individuals after taking aspirin or ti-
clopidine found that it took 3 days for the group who took 
aspirin, 5 days for the group who took ticlopidine, and 7 days 
for the group who took both aspirin and ticlopidine for the 
bleeding time to recover to that of baseline.
4
Colonoscopic polypectomy is considered to be a procedure 
with a high risk for bleeding, and these are commonly de-
fined as procedures with a greater than 1% risk of clinically 
significant bleeding requiring transfusion, hospitalization, 
endoscopic hemostasis, or surgery. 
If antithrombotic treatment is discontinued prior to an en-
doscopic procedure, the risk of developing thromboembolism 
is related to the patient’s underlying disease, and patients can 
be classified into either high- or low-risk groups (Table 2).
5 
For example, when antithrombotic treatment is withheld 
from patients with prosthetic valve replacements, the risk of 
serious thromboembolism is 4/100 patients per year;
6 how-
ever, if the patients receive an antiplatelet drug, such as aspi-
rin, this risk is reduced to 2.2/100 patients per year.
7
To date, no randomized controlled trial has evaluated whe-
ther the risk of bleeding is increased if aspirin is taken prior 
to a colonoscopic polypectomy, although there have been 2 
published prospective studies
8,9 and 3 published retrospective 
studies
10-12 (Table 3). The primary outcomes of these studies 
differed, as they included immediate bleeding, delayed bleed-
ing, as well as both immediate and delayed bleeding. Also, 
the definition of bleeding was not consistent; in some stud-
ies, bleeding was defined only as clinically significant bleed-
ing requiring transfusion or endoscopic hemostasis, whereas 
others included imperceptible bleeding that did not require 
any special treatments. These inconsistencies make the level 
of available evidence difficult to determine. 
In a prospective cross-sectional study by Shiffman et al.,
8 
the occurrence of delayed bleeding was more pronounced in 
the group that took either aspirin or nonsteroidal anti-in-
flammatory drugs compared to the group that took no drugs 
(22/228 [9.6%] vs. 8/236 [3.4%]). However, most bleeding 
events consisted of imperceptible amounts of bleeding with 
low clinical importance (22/228 [8.8%] vs. 6/236 [2.5%]; 
p=0.006), and the rates of critical bleeding for both groups 
were below 1%. In two retrospective case-control studies and 
one retrospective cross-sectional study, aspirin was not sho-
wn to be a risk factor for bleeding (OR, 1.1 [95% CI, 0.5 to 
2.2] to 1.4 [95% CI, 0.68 to 3.04]). Therefore, as aspirin con-
sumption prior to polypectomy procedures does not appear 
to be a risk factor for clinically significant delayed bleeding, 
aspirin does not need to be discontinued before this proce-
dure. 
Table 2. Risk Stratification for Thromboembolism
High risk condition 
Prosthetic heart valve in mitral position
Prosthetic heart valve and atrial fibrillation
Prosthetic heart valve and prior thromboembolic event
Low risk condition
Prosthetic heart valve in aortic position
Deep vein thrombosis
Atrial fibrillation without valvular heart disease
Bioprosthetic heart valveSH Lee et al. 
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In a prospective cross-sectional study by Kim et al.,
9 there 
was no difference between patients with or without immedi-
ate bleeding regarding their intake history of aspirin (6/215 
[2.8%] vs. 131/4,937 [2.5%]; p=0.9), and aspirin was not a 
risk factor for the development of immediate bleeding. How-
ever, the incidence of immediate bleeding that required en-
doscopic treatment was 0.2% for patients with polyps be-
tween 5 to 10 mm in size, 1.0% for those with polyps of 11 to 
19 mm, and 1.5% for those with polyps greater than 20 mm. 
Because the incidence of immediate bleeding increased as 
the size of the polyp increased (OR, 2.38; 95% CI, 1.78 to 
3.18; p<0.001), one could consider discontinuing aspirin for 
5 to 7 days prior to the procedure in patients with polyps 
larger than 10 mm and a low risk of thromboembolism. Fur-
thermore, we suggest that it is unnecessary for patients with 
no risk of thromboembolism to continue aspirin treatment 
prior to polypectomy.
Recently, due to the increased incidence of cardiovascular 
disease, the rates of administration of combined therapies 
with aspirin and anticoagulant or antiplatelet agents, such as 
clopidogrel, ticlopidine, or warfarin, have increased. It is dif-
ficult to evaluate the effects of these drugs on the risk of post-
polypectomy bleeding due to limited data, although it would 
be appropriate to compare the patient’s risk of thromboem-
bolism to the risk of post-polypectomy bleeding.
In conclusion, aspirin should be taken by patients with a 
high risk of developing thromboembolism. For patients with 
a low risk of thromboembolism, the discontinuation of aspi-
rin for 5 to 7 days prior to the treatment should be consid-
ered if the polyp is greater than 10 mm in size. For patients 
with no risk of embolism, aspirin therapy should be discon-
tinued, if possible. However, the physician who prescribed 
the aspirin treatment should be consulted before discontinu-
ing the drug. 
When diminutive polyps are found, is hot biopsy a recom-
mended method for their complete and safe removal?
Considering its complete resection rate, safety, and his-
tological quality, hot biopsy is not recommended method 
for removing diminutive polyps.
·Quality of evidence: low quality
· Strength of recommendation: strong recommenda-
tion
· Agreement level: completely agree (42%), generally 
agree (37%), partially agree (11%), generally disagree 
(5%), completely disagree (5%)
As the use of high-definition endoscopes has increased, 
the detection of diminutive polyps (<5 mm) has also in-
creased. According to recent reports, diminutive polyps are 
detected in more than half of screening tests, and more than 
half of these detected cases are diagnosed as adenomas.
13,14
Table 3. Studies on Aspirin Use Prior to Colon Polypectomy
Shiffman et al.8 Kim et al.9 Yousfi et al.10 Hui et al.11 Sawhney et al.12
Country  USA Korea USA Hong Kong USA
Study design Prospective  
cross-sectional
Prospective  
cross-sectional
Retrospective  
case-control
Retrospective  
cross-sectional
Retrospective  
case-control
Primary outcome (bleeding) Delayed  
(major, minor)
Immediate  
(major, minor)
Delayed  
(major)
Immediate and 
delayed (major, minor)
Delayed (major)
Total patient number/taking  
   aspirin/not taking aspirin
464/228/236 5,152/NA/NA 82/59/103 1,657/127/1,530 173/68/105
Patients (%) with major bleeding
   Among aspirin users
   Among controls
   Significance
2/228 (0.9)
2/236 (0.9)
NS
NA
NA
NA
NA
NA
NA
NA
NA
Patients (%) with minor bleeding
   Among aspirin users
   Among controls
   Significance
20/228 (8.8)
6/236 (2.5)
p=0.006
NA
NA
NA
NA
NA
NA
NA
NA
Patients (%) taking aspirin
   In bleeding group
   In non-bleeding group
   Significance 
NA
NA
NA
6/215 (2.8)
131/4,937 (2.5)
NS (p=0.90)
32/81 (39.51)
27/81 (33.33)
NS (OR, 1.41; 95% 
CI, 0.68-3.04)
3/37 (13.5)
122/1,620 (7.5)
NS (p=0.62)
17/41 (41.5)
51/132 (38.6)
NS (OR, 1.1; 95%  
CI, 0.5-2.2)
NA, not assessed; NS, not significant.16  Clin Endosc 2012;45:11-24
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The natural history of diminutive polyps may be different 
from that of adenomas larger than 6 mm, and endoscopic 
diagnosis and removal techniques remain controversial.
15 Is-
sues related to the removal of diminutive polyps can be sum-
marized as follows: 1) whether the diminutive polyp is com-
pletely removed, 2) the safety of the diminutive polyp remo-
val, and 3) the histological quality of the removed diminutive 
polyp. The methods that are currently used to remove diminu-
tive polyps include cold biopsy, hot biopsy, and cold snaring.
Only limited reports are available regarding the complete 
resection rate of diminutive polyps. From a randomized pro-
spective comparison study that compared the complete re-
section rate of hot and cold biopsy, residual lesions were de-
tected in 21% of patients administered hot biopsies and 29% 
of those given cold biopsies at the 3-week follow-up exami-
nation. There was no significant difference in the rate of re-
sidual disease in patients given either of these two methods.
16 
In two studies involving hot biopsy only, residual lesions 
were detected in 13% to 17% of patients.
17,18 Also, a recent 
prospective study found that when a lesion that had been 
completely removed by cold biopsy was re-excised with en-
doscopic submucosal resection, 61% of the lesion remained.
19 
Because a 31% to 61% rate of residual disease exists for both 
hot biopsy and cold biopsy, these techniques are not recom-
mended for complete resection (Table 4). Furthermore, there 
are no existing reports detailing the complete removal rate of 
the cold snaring procedure. 
In addition, there have been no reported randomized 
comparison studies to date regarding the safety of diminutive 
polyp removal. From 2 observational studies that included 
288 cold snaring cases and 907 hot biopsy cases, no observa-
tions were made regarding complications such as perforation 
or significant bleeding.
20,21 However, in a retrospective study 
that compared 436 cases of cold biopsy with 1,525 cases of 
hot biopsy, significant bleeding (0.39%) occurred in only 6 
hot biopsy cases.
22 In a retrospective survey study that exam-
ined 12,367 cases of hot biopsy, the rate of significant bleed-
ing was 0.37%, and that of perforation was 0.05%.
23 Ulti-
mately, because all of the reported complications were related 
to hot biopsy, this procedure is not recommended (Table 5).
In a randomized, prospective comparison study that eval-
uated the quality of the removed tissue, 39 (86.6%) out of 45 
lesions from hot biopsies and 42 (97.6%) out of 43 lesions 
from cold biopsies satisfied histological quality measures, 
and this difference was statistically significant. Therefore, 
cold biopsy is the recommended method for optimal histo-
logical quality.
24
In conclusion, due to the low complete resection rate, safe-
ty, and histological quality of hot biopsy, this procedure is not 
recommended for the removal of diminutive polyps.
Does submucosal injection help to prevent post-polypecto-
my bleeding?
Submucosal injection during polypectomy helps to pre-
vent early bleeding, but the preventative effect on delayed 
bleeding is not clear. 
·Quality of evidence: moderate quality
· Level of agreement: completely agree (13%), generally 
agree (53%), partially agree (16%), generally disagree 
(16%), completely disagree (2%)
For convenience and to reduce the danger of post-polyp-
ectomy bleeding, the submucosal injection of a variety of 
drugs has been developed. A mixture of normal saline and 
Table 4. Residual Rate after the Removal of Diminutive Polyps
Vanagunas et al.16 Peluso et al.17 Woods et al.18 Efthymiou et al.19
Country USA USA USA Australia
Study design Prospective case series Prospective case series Prospective randomized 
comparative
Prospective case series
Removal method  Hot biopsy Hot biopsy Cold biopsy vs.  
hot biopsy
Cold biopsy
Follow-up method Sigmoidoscopy 
4 wk
Sigmoidoscopy
1 or 2 wk
Sigmoidoscopy  
3 wk
EMR immediately after 
cold biopsy
Total polyp number
   Cold biopsy
   Hot biopsy
35
NA
35
62
NA
62
156
76
77
54
54
NA
Remnant lesion, %
   Among cold biopsy
   Among hot biopsy
   Significance 
NA
12/35 (34.3)
NA
11/62 (17.7)
16/76 (23)
21/77 (21)
NS
33/54 (61)
NA
NA, not assessed; NS, not significant.SH Lee et al. 
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epinephrine is the most commonly used solution. 
Our meta-analysis of 3 randomized prospective studies 
that compared post-polypectomy bleeding among patient 
groups that did or did not receive submucosal injection
25-27 
found that overall bleeding, including early bleeding (devel-
oping within 24 hours of the procedure) and delayed bleed-
ing (developing more than 24 hours after the procedure), de-
veloped in 6 (2.7%) out of 220 patients in the group that 
received submucosal injection and in 20 (8.6%) of the 232 
patients in the control group (RR, 0.33; 95% CI, 0.14 to 0.80; 
p<0.01) (Fig. 1). A subgroup analysis showed that early 
bleeding was experienced by 4 (1.8%) out of 220 patients in 
the group the received the injection and by 17 (7.3%) out of 
the 232 patients in the control group (RR, 0.27; 95% CI, 0.10 
to 0.74; p<0.01) (Fig. 2). However, 2 (0.9%) out of 220 pa-
tients in the injection group developed delayed bleeding, as 
compared to 3 (1.3%) out of 232 patients in the control 
group, and the two groups did not show any significant dif-
ferences (RR, 0.68; 95% CI, 0.11 to 4.01; p<0.67) (Fig. 3).
The submucosal injection of epinephrine is known to pre-
vent bleeding due to its effects of vascoconstriction and me-
chanical compression of blood vessels. Because this effect 
only lasts for a few hours, submucosal injection is thought to 
be effective only for early bleeding.
26-28
The concentration of epinephrine that was used for all 3 of 
the randomized prospective studies was 0.01%, but the in-
jected volumes were between 1 and 10 mL and differed be-
tween studies. Due to differences in the size and the shape of 
polyps, we are unable to conclude that submucosal injection 
should be performed for the prevention of early bleeding in 
all patients with polyps. Also, because submucosal injection 
can be effective not only preventing bleeding, but also in-
creasing the ease of polyp removal and reducing electrical 
tissue damage, decisions regarding its use should be left to 
the appropriate clinical judgment of the endoscopist. 
In conclusion, submucosal injection during polypectomy 
can be helpful for preventing early bleeding, but it does not 
appear to have a clear effect on delayed bleeding.
Are prophylactic procedures prior to polypectomies for 
large (>1 cm), pedunculated polyps helpful in preventing 
post-polypectomy bleeding?
Prophylactic procedures (e.g., loop or clip placement) help 
to prevent early bleeding during the removal of large (>1 
cm), pedunculated polyps, but the preventative effects of 
these procedures for delayed bleeding is not clear.
·Quality of evidence: moderate quality
· Level of agreement: completely agree (0%), generally 
agree (42%), partially agree (47%), generally disagree 
(11%), completely disagree (0%)
The known risk factors for post-polypectomy bleeding 
consist of patient-related factors, such as advanced age, med-
ical comorbidities, and drug regimens, as well as polyp-relat-
ed factors, such as shape, location, size, and grade of malig-
nancy.
11,29-32 Because large, pedunculated polyps are likely to 
have an associated thick feeding vessel within the neck, the 
risk of post-polypectomy bleeding in these cases is high.
31 En-
doscopic loop placement can mechanically compress the feed-
ing vessel within the neck, and clips have also been used for 
Table 5. Complication Rates after the Removal of Diminutive Polyps
Mann et al.20 Tappero et al.21 Tsai et al.22 Waddas et al.23
Country USA Italy USA USA
Study design Prospective case series Prospective case series Retrospective cross  
sectional
Retrospective survey
Removal method  Hot biopsy Cold snaring Cold biopsy vs. hot biopsy 
vs. cold snaring
Hot biopsy
Total patient number
Total polyp number
460
907
210
288
687
1,964
12,367
NA
Significant bleeding rate, %
   Among cold biopsy
   Among hot biopsy
   Among cold snaring 
   Significance 
Per polyp
NA
0
NA
Per polyp
NA
NA
0/288 (0)
Per polyp, per patient
0/436 (0), NA
6/1525 (0.39), 6/590 (1.02)
0/3 (0), NA
p<0.01
Per patient
NA
47/12,367 (0.38)
NA
Perforation rate rate, %
   Among cold biopsy
   Among hot biopsy
   Among cold snaring 
   Significance
Per polyp
NA
0
NA
Per polyp
NA
NA
0
Per polyp
0
0
0
NS
Per patient
NA
6/12,367 (0.05)
NA
NA, not assessed; NS, not significant.18  Clin Endosc 2012;45:11-24
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the same purpose.
33 However, there have been few randomi-
zed prospective studies that have compared the preventive 
effects of these mechanical compression methods to the ef-
fects of submucosal injection, and the few reported studies 
are inconsistent in terms of the selection of the prophylactic 
method and the comparison methods. 
When a meta-analysis was performed on 4 prospective 
randomized studies that had researched the risk of post-pol-
ypectomy bleeding associated with large (>1 cm), peduncu-
lated polyps treated with or without prophylactic procedures 
(loop or clip internment) prior to polyp removal,
27,34-36 early 
bleeding occurred in 3 (0.9%) out of the 326 patients who 
were given the prophylactic procedure, as compared to 24 
(5.1%) out of the 474 patients in the comparison group (RR, 
0.22; 95% CI, 0.08 to 0.62; p=0.004) (Fig. 4). Delayed bleed-
ing also developed in 3 (0.9%) of the 326 patients who were 
given the prophylactic procedure, as compared to 11 (2.3%) 
of the 474 patients in the comparison group (RR, 0.41; 95% 
CI, 0.12 to 1.41; p=0.16) (Fig. 5).
However, because the comparison group consisted of cases 
that had and had not received submucosal injection, differ-
ent results were obtained in the subgroup analysis. When we 
separated these patients who had received submucosal injec-
tions,
34,35 3 (1.1%) out of 279 patients who had received the 
prophylactic procedure were found to have developed early 
bleeding, whereas 12 (4.5%) out of 268 patients in the com-
parison group developed early bleeding. There was a decre-
ased occurrence of early bleeding in the prophylactic group, 
but this difference was not statistically significant (RR, 0.0; 
95% CI, 0.09 to 1.03; p=0.06) (Fig. 6). Delayed bleeding de-
veloped in 3 (1.1%) of the patients who had undergone the 
prophylactic procedure and in 5 (1.9%) patients in the com-
parison group. This difference was not significant (RR, 0.58; 
95% CI, 0.14 to 2.44; p=0.46) (Fig. 7). Furthermore, early 
Fig. 3. Efficacy of prophylactic saline with epinephrine injection prior to snare polypectomy for the prevention of late bleeding. CI, confi-
dence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 2 161 3 164 100.0% 0.68 [0.11, 4.01]
Hsieh et al.,26 2001 0 39 0 48 Not estimable
Rohde et al.,25 2000 0 20 0 20 Not estimable
Total (95% CI) 220 232 100.0% 0.68 [0.11, 4.01]
Total events 2 3
Heterogeneity: not applicable
Test for overall effect: Z=0.43 (p=0.67)
0.01 0.1 1 10 100
Favours injection Favours control
Fig. 1. Efficacy of prophylactic saline with epinephrine injection prior to snare polypectomy for the prevention of overall bleeding (early and 
late). CI, confidence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 5 161 13 164 73.9% 0.39 [0.14, 1.07]
Hsieh et al.,26 2001 0 39 2 48 8.3% 0.24 [0.01, 4.96]
Rohde et al.,25 2000 1 20 5 20 17.8% 0.20 [0.03, 1.56]
Total (95% CI) 220 232 100.0% 0.33 [0.14, 0.80]
Total events 6 20
Heterogeneity: Tau2=0.00; chi2=0.38, df=2 (p=0.83); I2=0%
Test for overall effect: Z=2.48 (p=0.01)
0.01 0.1 1 10 100
Favours injection Favours control
Fig. 2. Efficacy of prophylactic saline with epinephrine injection prior to snare polypectomy for the prevention of early bleeding. CI, confi-
dence interval.
Experimental Control    Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 3 161 10 164 64.0% 0.31 [0.09, 1.09]
Hsieh et al.,26 2001 0 39 2 48 11.5% 0.24 [0.01, 4.96]
Rohde et al.,25 2000 1 20 5 20 24.5% 0.20 [0.03, 1.56]
Total (95% CI) 220 232 100.0%  0.27 [0.10, 0.74]
Total events 4 17
Heterogeneity: Tau2=0.00; chi2=0.12, df=2 (p=0.94); I2=0%
Test for overall effect: Z=2.53 (p=0.01)
0.01 0.1 1 10 100
Favours injection Favours controlSH Lee et al. 
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bleeding developed in 2 (0.95%) out of 210 patients who re-
ceived snaring polypectomies without submucosal injec-
tion,
27,36 whereas this occurred in 12 (5.8%) out of the 206 
patients in the comparison group, and this difference was 
significant (RR, 0.20; 95% CI, 0.05 to 0.75; p=0.02) (Fig. 8). 
However, delayed bleeding developed in 1 patient (0.48%) in 
the procedural group and in 6 patients (2.9%) in the compar-
ing group, indicating that there was no significant preventive 
effect regarding delayed bleeding (RR, 0.23; 95% CI, 0.04 to 
1.40; p=0.11) (Fig. 9). In other words, for the removal of large 
pedunculated polyps, the use of loops, clips, or submucosal 
injections should be considered because all of these tech-
niques have been shown to prevent early bleeding. Endosco-
pists should select which method to use by considering the 
characteristics of the polyp, such as its location and shape.
In conclusion, prophylactic procedures that utilize loops 
or clips can prevent early bleeding during the removal of 
large (>1 cm) pedunculated polyps, although the preventive 
effect of these procedures on delayed bleeding is not clear.
Do prophylactic procedures for polypectomy-induced arti-
ficial ulcers decrease delayed bleeding?
Prophylactic procedures (e.g., argon plasma coagula-
tion or clip placement) for polypectomy-induced artificial 
ulcers do not decrease the occurrence of delayed bleeding. 
·Qualify of evidence: moderate quality
· Level of agreement: completely agree (13%), general-
ly agree (33%), partially agree (31%), generally dis-
agree (23%), completely disagree (0%)
Fig. 4. Efficacy of the prophylactic method (endoloop or clip application) for the prevention of early bleeding in cases with large pedunculat-
ed polyps. CI, confidence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 2 163 13 325 50.2% 0.31 [0.07, 1.34]
Ilish et al., 1996 0 47 2 42 12.1% 0.18 [0.01, 3.63]
Kouklakis et al.,34 2009 0 32 2 32 12.2% 0.20 [0.01, 4.01]
Paspatis et al.,35 2006 1 84 7 75 25.5% 0.13 [0.02, 1.01]
Total (95% CI) 326 474 100.0% 0.22 [0.08, 0.62]
Total events 3 24
Heterogeneity: Tau2=0.00; chi2=0.48, df=3 (p=0.92); I2=0%
Test for overall effect: Z=2.85 (p=0.004)
0.01 0.1 1 10 100
Favours prophylaxis Favours control
Fig. 5. Efficacy of the prophylactic method (endoloop or clip application) for the prevention of delayed bleeding in cases with large pedun-
culated polyps. CI, confidence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 1 163 5 325 33.8% 0.40 [0.05, 3.39]
Ilish et al., 2009 0 47 3 42 17.9% 0.13 [0.01, 2.41]
Kouklakis et al.,34 2009 1 32 2 32 28.0% 0.50 [0.05, 5.24]
Paspatis et al.,35 2006 1 84 1 75 20.4% 0.89 [0.06, 14.03]
Total (95% CI) 326 474 100.0% 0.41 [0.12, 1.41]
Total events 3 11
Heterogeneity: Tau2=0.00; Chi2=0.96, df=3 (p=0.81); I2=0%
Test for overall effect: Z=1.41 (p=0.16)
0.01 0.1 1 10 100
Favours prophylaxis Favours control
Fig. 6. Subgroup analysis of prophylactic methods versus submucosal injections for the prevention of early bleeding. CI, confidence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 2 163 3 161 47.9% 0.66 [0.11, 3.89]
Kouklakis et al.,34 2009 0 32 2 32 16.8% 0.20 [0.01, 4.01]
Paspatis et al.,35 2006 1 84 7 75 35.2% 0.13 [0.02, 1.01]
Total (95% CI) 279 268 100.0% 0.30 [0.09, 1.03]
Total events 3 12
Heterogeneity: Tau2=0.00; chi2=1.52, df=2 (p=0.47); I2=0%
Test for overall effect: Z=1.91 (p=0.06)
0.01 0.1 1 10 100
Favours prophylaxis Favours injection20  Clin Endosc 2012;45:11-24
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Bleeding is the most common complication of polypecto-
my.
37 Several recent reports have documented bleeding fre-
quencies between 0.4% and 0.9%, and these are lower than 
they have been in the past.
9,12 However, delayed bleeding cau-
ses significant clinical problems (e.g., the need for hospitaliza-
tion, transfusion, repeated endoscopy or surgery).
38 To prevent 
delayed bleeding, many methods, such as submucosal injec-
tions and clip or loop placements, have been used clinically. 
However, prospective comparison studies are scarce, and 
there is currently no established guideline. Because the rate 
of delayed bleeding is typically below 1%, a large number of 
patients are required to demonstrate beneficial effects of a 
given prophylactic procedure. Furthermore, many factors re-
lated to bleeding, such as the polyp, patient, and procedural 
characteristics, are known to interact in a complex fashion. 
Prospective data regarding the use of prophylactic proce-
dures for polypectomy-induced artificial ulcers, excluding 
procedures for pedunculated polyps, are very limited. A me-
ta-analysis was performed on 2 prospective randomized 
studies that evaluated argon plasma coagulation and hemo-
clipping,
39,40 and this report found that 8 (0.02%) out of 396 
patients who received the prophylactic procedure developed 
delayed bleeding, as compared to 12 (0.03%) of the 402 pa-
tients in the control group, and this difference between 
groups was not statistically significant (RR, 0.67; 95% CI, 0.27 
to 1.61; p=0.37) (Fig. 10). 
Both of these studies were performed on patients with pol-
yps between 0.5 and 2 cm in size. In the study that evaluated 
the use of argon plasma coagulation, all of the 803 polyps ex-
amined were non-peduculated. However, in the study that 
used clips, patients with pedunculated polyps (31 cases, 0.08%) 
were included in the total of 413 patients with polyps. And 
also in both studies, cases with immediate bleeding were ex-
cluded, which enables this result to be applied to cases of non-
pedunculated polyps (<2 cm) without immediate bleeding.
In conclusion, prophylactic procedures using argon plas-
ma or clips to prevent polypectomy-induced artificial ulcers 
do not decrease the occurrence of delayed bleeding.
When do we request additional colon resection to exclude 
the possibility of lymph node metastasis for cases where the 
histology is positive for adenocarcinoma with submucosal 
invasion and where complete excision (negative resection 
margin) has been obtained following the polypectomy?
If the histology indicates the presence of adenocarcino-
ma with submucosal invasion and complete excision 
(negative resection margin) was achieved following the 
polypectomy, the additional surgical excision should be 
considered because the danger of lymph node metastasis 
increases if there is lymphatic or venous invasion, poor 
differentiation, or deep submucosal invasion.
·Quality of evidence: low quality
· Strength of recommendation: strong recommenda-
tion
· Agreement level: completely agree (26%), generally 
agree (55%), partially agree (19%), generally disagree 
(0%), completely disagree (0%)
Fig. 7. Subgroup analysis of prophylactic methods versus submucosal injections for the prevention of delayed bleeding. CI, confidence in-
terval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 1 163 2 161 35.9% 0.49 [0.05, 5.39]
Kouklakis et al.,34 2009 1 32 2 32 37.1% 0.50 [0.05, 5.24]
Paspatis et al.,35 2006 1 84 1 75 27.0% 0.89 [0.06, 14.03]
Total (95% CI) 279 268 100.0% 0.58 [0.14, 2.44]
Total events 3 5
Heterogeneity: Tau2=0.00; chi2=1.13, df=2 (p=0.94); I2=0%
Test for overall effect: Z=0.74 (p=0.46)
0.01 0.1 1 10 100
Favours prophylaxis Favours injection
Fig. 8. Subgroup analysis of the prophylactic method versus no injection for the prevention of early bleeding. CI, confidence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 2 163 10 164 80.0% 0.20 [0.04, 0.90]
Ilish et al., 1996 0 47 2 42 20.0% 0.18 [0.01, 3.63]
Total (95% CI) 210 206 100.0% 0.20 [0.05, 0.75]
Total events 2 12
Heterogeneity: Tau2=0.00; chi2=0.00, df=1 (p=0.94); I2=0%
Test for overall effect: Z=2.37 (p=0.02)
0.01 0.1 1 10 100
Favours prophylaxis Favours controlSH Lee et al. 
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Malignant polyps occur when the cancer cells penetrate 
through the muscularis mucosae and invade the submuco-
sa.
41 These lesions differ from intramucosal cancer, for which 
a follow-up is performed without additional resection be-
cause the risk of lymph node metastasis is very low. If cancer 
cells invade the submucosa, which contains many lymphatic 
and blood vessels, the possibility of lymph node metastasis is 
relatively high. The treatment of this condition is therefore 
controversial.
42-44
However, there have been few well-designed prospective 
studies regarding malignant polyps. Most studies are retro-
spective analyses of patients who underwent surgical exci-
sion for early CRC. When these retrospective studies were 
analyzed (Table 6),
45-51 67.5% (143/212) of the cases with 
Table 6. Studies of Malignant Polyp Invading the Submucosa in Surgically Resected Colorectal Specimens
Yamamoto et al.45 Egashira et al.46 Tominaga et al.47 Yasuda et al.48 Ishikawa et al.49 Tateishi et al.50 Kitajima et al.51
Country  Japan Japan Japan Japan Japan Japan Japan
Study design Retrospective 
cross-sectional
Retrospective 
cross-sectional
Retrospective 
cross-sectional
Retrospective 
cross-sectional
Retrospective 
cross-sectional
Retrospective 
cross-sectional
Retrospective 
cross-sectional
Total patient number/
LN (+) group/LN (-) 
group
301/19/282 140/13/127 155/19/136 86/21/65 71/28/43 322/46/276 865/87/778
Lymphatic invasion
   LN (+) group, %
   LN (-) group, %
13/19 (68.4)
76/282 (27.0)
12/13 (92.3)
35/127 (27.6)
12/19 (63.2)
27/136 (19.9)
NA
NA
18/28 (64.3)
4/43 (9.3)
25/46 (54.3)
51/276 (18.5)
63/87 (72.4)
213/778 (27.4)
Venous invasion
   LN (+) group, %
   LN (-) group, %
NA
NA
5/13 (38.5)
11/127 (8.7)
4/19 (21.1)
16/136 (11.8)
18/21 (85.7)
23/65 (35.4)
8/28 (28.6)
6/43 (14.0)
13/46 (28.3)
32/276 (11.6)
36/87 (41.4)
158/778 (20.3)
Pathology 
   LN (+) group
   LN (-) group
WD/MD/PD
12/6/1
218/61/3
WD/MD/PD/
Others
2/9/0/2
65/53/2/7
WD/MD/PD
6/12/1
101/34/1
WD/MD&PD
10/11
54/11
WD/MD/PD/
Others
6/11/9/2
25/14/2/2
WD/MD&PD
23/23
225/51
WD&MD/PD
85/2
774/4
Invasion depth, μm 
   LN (+) group
   LN (-) group
<1,000/≥1,000
3/16
166/116
NA
NA
<1,000/1,000-
2,000/>2,000
0/3/16
26/25/85
<1,000/1,000-
2,000/>2,000
0/4/17
21/15/29
NA
NA
NA
NA
<1,000/1,000-
2,000/>2,000
3/18/66
190/134/454
LN, lymph node; WD, well-differentiated; MD, moderate-differentiated; PD, poorly-differentiated; NA, non-assessed.
Fig. 9. Subgroup analysis of the prophylactic method versus no injection for the prevention of delayed bleeding. CI, confidence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Di Giorgio et al.,27 2004 1 163 3 164 62.9% 0.34 [0.04, 3.19]
Ilish et al., 1996 0 47 3 42 37.1% 0.13 [0.01, 2.41]
Total (95% CI) 210 206 100.0% 0.23 [0.04, 1.40]
Total events 1 6
Heterogeneity: Tau2=0.00; chi2=0.26, df=1 (p=0.61); I2=0%
Test for overall effect: Z=1.59 (p=0.11)
0.01 0.1 1 10 100
Favours prophylaxis Favours control
Fig. 10. Efficacy of the prophylactic method (argon plasma coagulation or clip application) for the prevention of delayed bleeding. CI, confi-
dence interval.
Experimental Control   Risk ratio Risk ratio
Study or subgroup Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI
Lee et al.,39 2009 6 240 10 235 0.59 [0.22, 1.59]
Shioji et al.,40 2003 2 156 2 167 1.07 [0.15, 7.51]
Total (95% CI) 396 402 0.67 [0.27, 1.61]
Total events 8 12
Heterogeneity: Tau2=0.00; chi2=0.29, df=1 (p=0.59); I2=0%
Test for overall effect: Z=0.90 (p=0.37)
0.01 0.1 1 10 100
Favours prophylaxis Favours control22  Clin Endosc 2012;45:11-24
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lymph node metastases had lymphatic invasion of the exci-
sion tissue, which is significantly higher than the 24.7% 
(406/1,642) of patients in the group without lymph node me-
tastases who demonstrated invasion (OR, 7.33; 95% CI, 5.29 
to 10.15). Venous invasion was present in 39.3% (84/214) of 
patients with lymph node metastases, which is significantly 
higher than the 17.3% rate of venous invasion (246/1,425) in 
the group without lymph node metastases (OR, 3.24; 95% CI 
2.34 to 4.48). Also, the well-differentiated (WD), moderately 
differentiated (MD), and poorly differentiated (PD) cases 
represented 59/146 (40.4%), 38/79 (48.1%), and 13/166 
(7.8%) cases in the group with lymph node metastases, re-
spectively, and 688/929 (74.1%), 162/588 (27.6%), and 
12/1,366 (0.9%) cases in the group without lymph node me-
tastases, respectively. The proportion of differentiated can-
cers in the group with lymph node metastasis was low (OR 
in WD, 0.23; 95% CI, 0.15 to 0.34; OR in MD, 2.39; 95% CI 
1.43 to 3.98; OR in PD, 6.31; 95% CI, 2.52 to 15.79). The rates 
of submucosal invasion that was less than 1,000 μm, between 
1,000 and 2,000 μm, or greater than 2,000 μm were 19/146 
(13.0%), 25/127 (19.7%), and 99/127 (78.0%) for the group 
with lymph node metastases, respectively, and 403/1,261 
(32.0%), 174/979 (17.8%), and 539/979 (55.1%) for the group 
without lymph node metastases, respectively. Therefore, there 
was deeper submucosal invasion as the metastasis of the 
lymph nodes progressed (OR in <1,000 μm, 0.31; 95% CI, 
0.18 to 0.54; OR in 1,000 to 2,000 μm, 1.10; 95% CI, 0.69 to 
1.76; OR in >2,000 μm, 3.39; 95% CI, 2.19 to 5.25).
However, as the actual risk for lymph nodes metastasis in 
patients with high risk factors is approximately 10% to 15%, 
careful decision making is required prior to the recommen-
dation for additional surgery. Furthermore, the effects of 
medical comorbidities and patient age should also be consid-
ered.
In conclusion, when histology indicates the presence of 
adenocarcinoma with submucosal invasion and when com-
plete excision (negative resection margin) has been achieved 
following the polypectomy, additional surgical excision 
should be considered if there is lymphatic or venous inva-
sion, if the polyp is PD, or if there is deep submucosal inva-
sion.
SUMMARY
1.   The use of aspirin should continue prior to the polypec-
tomy for individuals with a high risk of developing 
thromboembolism. For those with a lower risk of devel-
oping thromboembolism, the aspririn treatment regimen 
should be determined according to the characteristics of 
the patients and their polyps. For those with no risk of 
developing thromboembolism, it is recommended that 
aspirin treatment be discontinued prior to polypectomy.
2.   Considering its complete resection rate, safety, and his-
tological quality, hot biopsy is not recommended for re-
moving diminutive polpys.
3.   Submucosal injection during polypectomy helps to pre-
vent early bleeding, but the preventative effect on delayed 
bleeding is not clear. 
4.   Prophylactic procedures (e.g., loop or clip placement) 
help to prevent early bleeding during the removal of 
large (>1 cm), pedunculated polyps, but the preventative 
effects of these procedures for delayed bleeding is not 
clear.
5.   Prophylactic procedures (e.g., argon plasma coagulation 
or clip placement) for polypectomy-induced artificial ul-
cers do not decrease the occurrence of delayed bleeding. 
6.   If the histology indicates the presence of adenocarcino-
ma with submucosal invasion and complete excision 
(negative resection margin) was achieved following the 
polypectomy, the additional surgical excision should be 
considered because the danger of lymph node metastasis 
increases if there is lymphatic or venous invasion, poor 
differentiation, or deep submucosal invasion.
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